Shaily Engineering Plastics Ltd (SHAILY) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated August 03, 2026 3 min read

Shaily Engineering Plastics faces a pivotal quarter as it balances rapid expansion in its high-margin healthcare vertical against a cyclical downturn in its legacy home furnishing business. Investors will be looking for signs of margin resilience driven by export-led rupee tailwinds and the ramp-up of new pen-injector capacity.

Quick Details

Results date	August 08, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 236.8 Cr
Previous quarter PAT	Rs. 40.2 Cr
Previous quarter EBITDA margin	29.3%
Net debt (latest quarter)	Rs. 148.86 Cr
Market cap	Rs. 14080.99 Cr
CMP	Rs. 3061.4

Shaily Engineering Plastics Ltd Q1 Results Date and Time

The board meeting is scheduled for August 08, 2026, to consider the audited financial results for Q1 FY27.

What to expect from Shaily Engineering Plastics Ltd's Q1 FY27 results

Shaily is expected to show revenue growth led by its healthcare segment, which reached a quarterly baseline of Rs. 113 Cr in Q4 FY26 and is supported by new pen-injector capacity. The company benefits from a significant export tailwind, as the rupee averaged Rs. 94–95/USD during the quarter compared to the Rs. 87 zone in Q4 FY26, which is expected to support margin expansion. While the consumer home furnishing segment remains weak—with revenue down 31% YoY in Q4 FY26—the industrial segment is projected to continue its growth trajectory, having posted 41% YoY growth in FY26. Management's ability to maintain EBITDA margins near the 29.3% level seen in Q4 FY26 will be a key focus, especially as the firm navigates rising employee and other expenses which grew 27% YoY in the previous quarter.

Key Things To Watch

Performance vs Guidance Tracking

Pen injector production — 36 Mn units target for FY27 — Q1 run-rate tracking
Pen capacity addition — 25 Mn units planned for Jul/Aug 2026 — commissioning status
Combined pen output — 40-42 Mn units target by year-end — ramp trajectory

Healthcare Segment Growth

Q1 healthcare revenue run-rate vs Rs. 113 Cr baseline in Q4 FY26
Status of ShailyPen Neo commercial adoption in India and Canada
Progress on semaglutide pen capacity installation target of 50 Mn units

Abu Dhabi Facility and Fundraising

Update on potential financial support discussions with Abu Dhabi government for Rs. 300-350 Cr project
Clarity on quantum, instrument, and use of proceeds for the Rs. 500 Cr enabling resolution passed May 19, 2026

Consumer Segment Pivot

Demand trends in European and US home furnishing markets following 31% YoY revenue decline in Q4 FY26
Early revenue contribution and pipeline progress for consumer electronics and semiconductor trays

Risks and headwinds to monitor

Impact of June 2026 promoter stake sale of 2.27% on governance perception
Supply chain resilience and volatility in resin availability flagged as increasing risks

Frequently Asked Questions

How did Shaily's healthcare segment perform in the previous quarter?

The healthcare segment reported revenue of Rs. 113 Cr in Q4 FY26, representing a 101% increase compared to Q4 FY25. This segment now contributes approximately 40% of total revenue.

What is the status of Shaily's pen injector capacity?

As of Q4 FY26, the company had a total pen injector capacity of 80 Mn units per year. Management is targeting a combined pen output of 40-42 Mn units by the end of FY27.

What are the company's plans for the Abu Dhabi facility?

The company is investing Rs. 300-350 Cr in an Abu Dhabi facility with a capacity of approximately 75 Mn pen/auto-injectors per year. The facility is expected to be operational by Q4 FY28.